Dicerna Pharmaceuticals (NASDAQ:DRNA) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
Other analysts have also recently issued research reports about the stock. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a research note on Friday, November 3rd. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Dicerna Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $6.81.
Shares of Dicerna Pharmaceuticals (DRNA) opened at $8.47 on Tuesday. The company has a market cap of $452.38, a PE ratio of -2.47 and a beta of 2.85. Dicerna Pharmaceuticals has a twelve month low of $2.42 and a twelve month high of $10.24.
In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv acquired 285,000 shares of the company’s stock in a transaction on Monday, December 18th. The stock was acquired at an average price of $7.00 per share, for a total transaction of $1,995,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 29.41% of the stock is owned by insiders.
Several large investors have recently modified their holdings of the company. Northern Trust Corp raised its position in shares of Dicerna Pharmaceuticals by 6.1% in the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 2,094 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after buying an additional 14,517 shares in the last quarter. Palo Alto Investors LLC raised its position in shares of Dicerna Pharmaceuticals by 4.0% in the 2nd quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock valued at $1,588,000 after buying an additional 19,394 shares in the last quarter. Birchview Capital LP raised its position in shares of Dicerna Pharmaceuticals by 125.0% in the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock valued at $259,000 after buying an additional 25,000 shares in the last quarter. Finally, Deschutes Portfolio Strategy LLC acquired a new position in shares of Dicerna Pharmaceuticals in the 3rd quarter valued at approximately $575,000. Institutional investors own 41.29% of the company’s stock.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
What are top analysts saying about Dicerna Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dicerna Pharmaceuticals and related companies.